While 2023 net revenue was 26% lower than that peak, as interest rates and economic uncertainty increased, the firm appears to have stabilized and looks poised for a return to high-single-digit ...
Investing.com -- Evercore ISI added Wendy’s Co to its Tactical Outperform list ahead of the company’s investor day on March 6 ...
Shares of Vera Therapeutics (VERA) sold off about 20% on Friday following news in competitor Otsuka’s 2024 earnings presentation that the ...
Mike “Magicman” Byrne has been a part of the MMOBomb family for years and serves as the site’s current Editor-in-Chief. His ...
Specialty MGA Optio Group has retained investment bank Evercore with a mandate to explore its debt options, as the business ...
Evercore ISI analyst Liisa Bayko maintained a Buy rating on Ultragenyx Pharmaceutical (RARE – Research Report) on February 14 and set a price ...
Evercore ISI has upgraded CRISPR (CRSP) to outperform from in line, citing upcoming data catalysts. Read more here.
Evercore ISI analysts upgraded CRISPR Therapeutics stock from an In Line to an Outperform rating and increased the price target significantly to $99 from the previous $60. The upgrade comes as ...
Evercore ISI analyst Liisa Bayko raised the price target for CRISPR Therapeutics from $60.00 to $99.00. Bayko's optimism is driven by upcoming catalysts that could mark a new chapter for the company.